An observational study in Stroke, sponsored by Poitiers University Hospital. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Poitiers University Hospital · Observational
Numerous patients are addressed to the Emergency Department for unspecific symptoms which can evoke a stroke, such as vertigo, isolated motor deficit, behavior disorder.
For these patients, when they arrive out of time for specific treatments such as thrombolysis and thrombectomy, the cerebral imagery is not an emergency, but necessary to confirm or invalidate the diagnostic of stroke.
If a biomarker could exclude the diagnostic of stroke, we could avoid an imagery for these patients.
PS100B is a biomarker whose blood level increases in case of stroke. It has already proven a prognostic value. Until now, it hasn't proven a diagnostic value because it take a few hours to increase in the blood.
It could have in prognostic value for patients who have the symptoms for more than 24 hours.
STROkE is a diagnostic, prospective, monocentric study, conducted at University Hospital Center of Poitiers (France).
The aim is to determine the value of PS100B to exclude the diagnostic of a stroke in case of evocative symptoms, for patients who are out of delay for a thrombolysis or a thrombectomy.
Patients eligible are the ones who present to the emergency department with symptoms evocative of stroke for more than 24 hours and less than 4 days. Patients included have a sample of blood withdrawn, in order to measure PS100B blood level.
The diagnostic of stroke is than confirmed or excluded by an adjudication comity, who are unaware of the result of PS100B blood level.
The diagnostic value of PS100B is determined with the help of a ROC curve.
7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.
This study's enrollment of 179 is above the median of 160 across 1,692 observational studies indexed under Stroke.
Browse Stroke studies →Poitiers University Hospital is the lead sponsor of 310 studies on the registry; 64 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients presenting at the Emergency Department of the University Hospital Center of Poitiers for symptoms evocative of stroke for more then 24 hours and less then 4 days, that fit the inclusion and exclusion criteria
Exclusion Criteria:
Diagnostic value of PS100B
Determine the best couple sensibility / specificity of the blood value of PS100B with the help of a Receive Operating Charasteristics (ROC) curve for patients who present with symptoms evocative of stroke since more than 24 hours and less than 4 days
Time frame: 1 day
Value of PS100B for ischemic strokes and hemorrhagic strokes
Comparison of the mean value of PS100B between patients with ischemic strokes and hemorrhagic strokes
Time frame: 1 day
Value of PS100B and time delay since the beginning of the symptoms
Stratification of the value of PS100B with the delay of apparition of the symptoms and realization of the blood sample
Time frame: 1 day
Prognostic value of PS100B
Comparison of the value of PS100B and the patient's outcomes 28 days after inclusion. The patient's outcome will be assessed as follow : hospitalization, death and self-rated health perception. The self-rated health perception will be assessed with the scale EuroQOL (EQ)-5D-5L. The scale EQ-5D-5L is composed of : * a score on 5 levels : from 1 to 3 (no problem) and 4 to 5 (with problems) * analogic scale from 0 to 100 (0 = worst health perception ; 100 = best health perception)
Time frame: 28 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital